and we have fast-track research and guidance.

Historically, NIH has focused almost solely on politically safe and

entirely fruitless research about the genetic drivers of autism.

And that would be like studying the genetic drivers of lung cancer without looking at cigarettes.

And that's what NIH has been doing for 20 years.

As a result, we don't have an answer to this critical question,

despite the cataclysmic impact of the epidemic on our nation's children.

We are now replacing the institutional culture of politicized science and corruption with evidence-based medicine.

NIH research teams are currently testing multiple hypotheses with no area off-limits.

We promise transparency as we uncover the potential causes and treatments,

and we will notify the public regularly of our progress.

Today, we are announcing two important findings from our autism work that are vital for parents to know as they make these decisions.

First, HHS will act on acetametaphim.

The FDA is responding to clinical and laboratory studies that suggest a potential association

between acetametaphine used during pregnancy and adverse neurodevelopmental outcomes,

including later diagnosis for ADHD and autism.

Scientists have proposed biological mechanisms

linking prenatal acetamapentin exposure

to altered brain development.

We have also evaluated the contrary studies

that show no association.

Today, the FDA will issue a physician's notice about the risk of acetamapin during pregnancy

...